| Literature DB >> 24359594 |
Peter Siig Vestentoft, Peter Jelnes, Jesper B Andersen, Thi Anh Thu Tran, Tenna Jørgensen, Morten Rasmussen, Jette Bornholdt, Lene Melsæther Grøvdal, Charlotte Harken Jensen, Lotte Katrine Vogel, Snorri S Thorgeirsson, Hanne Cathrine Bisgaard1.
Abstract
BACKGROUND: Tissue repair in the adult mammalian liver occurs in two distinct processes, referred to as the first and second tiers of defense. We undertook to characterize the changes in molecular constituents of the extracellular matrix when hepatic progenitor cells (HPCs) respond in a second tier of defense to liver injury.Entities:
Year: 2013 PMID: 24359594 PMCID: PMC3892118 DOI: 10.1186/1755-1536-6-21
Source DB: PubMed Journal: Fibrogenesis Tissue Repair ISSN: 1755-1536
Identification of ECM constituents modulated in first and second tiers of defense upon hepatic injury
| Keratin 19 | ⇅ | ↑ * | +++++ M | |
| α-Fetoprotein | ⇅ | ↑ * | +++++ M | |
| Epithelial cell adhesion molecule, EpCam | ⇅ | ↑ * | +++++ M | |
| Delta-like homolog 1 | ⇅ | ↑ * | +++++ M | |
| Deleted in malignant brain tumor 1 | ⇅ | ↑ * | +++++ M | |
| Glutathione S-transferase, pi | ⇅ | ↑ * | +++++ M | |
| Gap junction protein, α1 (Cx43) | ⇅ | ↑ * | +++++ M | |
| Prominin, CD133 | ⇅ | ↑ * | +++++ M | |
| CD24 | ⇅ | ↑ * | +++++ M | |
| Vimentin | ⇅ | ↑ * | +++++ M | |
| Proliferating cell nuclear antigen | ↑ * | ↑ | +++++ | |
| Desmin | ↑ | ↑ | +++ | |
| S100 calcium-binding protein A4 | ↑ | ↑ | ++++ | |
| Secreted phosphoprotein 1 (osteopontin) | ↑ | ↑ | ++++ | |
| Agrin | ↓ * | ↑ * | +++++ M | |
| Biglycan | ↓ * | ↑ * | +++++ M | |
| Decorin | ↑ * | ↑ | ++++ | |
| Elastin | ↑ * | ↑ | +++++ | |
| Fibrillin 1 | ⇅ | ↑ * | +++++ M | |
| Fibronectin 1 | ↓ * | ↑ * | +++ | |
| Fibulin 1 | ↓ | ↓ | ++++ | |
| Collagens | ↑ | ↑ | +++++ | |
| | ↑ | ↑ * | +++++ | |
| | ↑ * | ↑ * | +++++ | |
| | ⇅ | ↑ * | +++++ M | |
| | ↑ | ↑ * | +++++ | |
| | ↑ | ↑ * | +++++ | |
| | ↑ | ↑ * | +++++ | |
| | ↑ | ↑ * | +++++ | |
| | ↓ | ↑ * | +++++ | |
| | ⇅ | ↑ * | +++++ M | |
| | ↑ * | ↑ * | ++++ | |
| | ↑ | ↑ * | +++++ | |
| | ↓ | ⇅ | +++ | |
| Laminins | ↓ * | ↑ | +++++ | |
| | ⇅ | ↑ * | ++ M | |
| | ⇅ | ↑ * | +++++ M | |
| | ↓ * | ↑ * | ++++ M | |
| | ↑ * | ↑ * | ++ | |
| | ⇅ | ↑ | +++++ | |
| Integrins | ↑ | ↓ | ++ | |
| | ↓ | ↑ * | ++++ M | |
| | ↓ | ↓ | +++ | |
| | ↓ | ↓ * | +++ | |
| | ↑ | ↑ * | ++++ | |
| | ↓ * | ↑ * | +++++ M | |
| | ⇅ | ↑ * | +++++ M | |
| | ⇅ | ↑ * | +++++ M | |
| | ↑ | ↑ * | +++ | |
| Nidogens | ↑ * | ↑ * | +++++ M | |
| | ↓ | ↑ * | +++++ M | |
| Secreted protein, acidic, cysteine-rich, (osteonectin, SPARC) | ↑ * | ↑ * | +++++ | |
| Matrix metallopeptidases | ↓ | ↓ | ++++ | |
| | ⇅ | ⇅ | +++ | |
| | ↑ | ↑ * | +++++ M | |
| | ↓ | ↑ * | +++ | |
| | ↑ | ↑ | +++ | |
| | ⇅ | ↑ * | +++ | |
| | ↑ | ↑ * | ++++ M | |
| TIMP metallopeptidase inhibitor 1 | ↑ | ↑ * | ++ | |
| A disintegrin and metalloproteinase with thrombospondin motifs 1 | ↓ | ↑ | +++++ | |
| Suppression of tumorigenicity 14 (matriptase) | ⇅ | ↑ * | +++++ M | |
| Connective tissue growth factor | ⇅ | ↑ * | +++++ M | |
| Elastin microfibril interfacer 1 | ↑ | ↑ * | ++++ | |
| Glypican 3 | ↓ | ↑ * | +++++ M | |
| Periostin, osteoblast specific factor | ↑ | ↑ | +++++ | |
| Syndecans | ↑ * | ↑ | ++++ | |
| | ↓ * | ↓ * | +++ | |
| Hepatocyte growth factor | ⇅ | ↑ * | +++ | |
| Hepatocyte growth factor activator | ↓ | ↓ | +++ | |
| Hepsin | ↓ | ↓ * | +++ | |
| Kallikrein B, plasma 1 | ↓ | ↓ * | ++++ | |
| Plasminogen | ↓ * | ↓ * | +++ | |
| Plasminogen activator, urokinase | ↑ | ↑ * | +++ | |
| Protease, serine, 1 (trypsin 1) | ⇅ | ↑ | +++++ | |
| Protease, serine, 8 (prostasin) | ↑ | ↑ | ++++ | |
| Serine peptidase inhibitor, Kunitz type 1 (HAI-1) | ⇅ | ↑ | +++++ | |
| Serine peptidase inhibitor, Kunitz type 2 (HAI-2) | ↓ * | ↓ * | ++ | |
| Serine peptidase inhibitor, clade A (α-1 antiproteinase), member 1 | ↓ * | ↓ | +++ | |
| Serine peptidase inhibitor, clade C (antithrombin), member 1 | ↓ | ↓ | +++++ | |
| Serine peptidase inhibitor, clade F (α-2 antiplasmin), member 1 | ↓ * | ↓ * | +++++ | |
A hypothetical list of constituents involved in extracellular matrix remodeling based on existing literature (See text for details). A list of significantly up- or down-modulated transcripts is provided in Additional file 1 and a graphic illustration of signal intensities in Additional file 2. Transcriptional profile: ↓, down-modulated; ↑, up-modulated; ⇅, not modulated. Correlation strength: +++++, 0.90 to 1.00, very strong; ++++, 0.70 to 0.89, strong; +++, 0.40 to 0.69, modest; ++, 0.20 to 0.39 weak; + 0.00 to 0.19, very weak. M, transcript levels modulated mainly in the second tier of defense. *Significantly modulated transcripts (P < 0.01, false discovery rate (FDR) < 5%). The product–moment correlation coefficient (r) was calculated for signal intensities between transcripts of interest relative to Krt1-19, a marker of the hepatic duct/progenitor cells.
Figure 1Expression of matriptase network in hepatic injury. (A) Real-time RT-PCR analysis. Elevated expression levels of Spint1, St14, Prss8, and Krt1-19 transcripts were particularly evident in the two liver injury protocols with HPC-responses. While Krt1-19 transcripts were significantly increased up to 7-fold on day 14 in the BDL protocol, HPC response showed the highest induction, with increases from 3- to 40-fold on days 1 through 9 in the AAF/PHx protocol and from 4- to 60-fold at weeks 1 through 4 in the CDE protocol. Similar expression patterns were obtained for St14 and Spint1 transcripts. Where St14 was increased 2.6- to 7-fold in the PHx and BDL protocols, a 45- to 90-fold increase was observed on week 4 in the CDE and on day 9 in the AAF/PHx protocols, respectively. Similarly, Spint1 reached a 90- to 105-fold increase on week 3 in the CDE and day 9 in AAF/PHx protocols, whereas Prss8 increased 16- to 18-fold, respectively. In control and sham protocols, significant changes in gene expression were not detected. Values are relative to the uninjured control group ± standard deviation (*P < 0.05; †P < 0.001). Very strong positive correlations were observed between expression values for Spint1 and St14 and the progenitor cell marker Krt1-19. (b) Triple immunofluorescence localized: (a) matriptase, (b) HAI-1, and (c) OV6/Krt19 to both the cholangiocytes and HPC response. (a-d) Dlk1 marked a subpopulation of matriptase or HAI-1-positive cells in the HPC response. (c,d) Nidogen1 closely encircled the tortuous structures in the HPC response. (e-g) HAI-1 was expressed by cholangiocytes and HPCs regardless of type of hepatic insult. Dlk1, however, was only located to a subpopulation of cells in the HPC response. Magnification: 10×; inserts 40×.
Figure 2Protein of the basal lamina and other ECM structural constituents are localized similarly across rat hepatic injury protocols. In the sham, BDL, and AAF/PHx protocols, (a-d) Collagen1a1, (e-h) laminin, and (i-l) nidogen1 stained the portal vein endothelia and closely circumscribed cells in the biliary tree and HPC response. Collagen1a1 deposition was additionally observed in the parenchyma. In the canals of Hering, staining for HAI-1 often extended beyond the extracellular matrix (inserts in c,g,j). (d,h,l) The Dlk1 expressing subpopulation of cells in the AAF/PHx protocol was always in contact with the extracellular matrix. In the BDL and AAF/PHx protocols, (n-p) Ki67-positive cells were observed both within (n,o) the HAI-1- and (p) the Dlk1-positive cell populations. Ki67-positive cells were, however, rarely detected in (m) the sham protocol. In the sham protocol, (q) desmin prominently stained the portal vein endothelia and the portal artery, while faintly marking occasional star-shaped cells near the biliary tree or in the parenchyma. Regardless of injury type, in both the (r) BDL and (s,t) AAF/PHx protocols, numerous desmin-positive star-shaped cells closely escorted the biliary tree and HPC response.
Figure 3Three-dimensional reconstruction of injured rat liver mounting a HPC response. Three-dimensional (3D) reconstructions of 208 μm rat liver tissue demonstrated protein expression in control liver (A) and liver from day 9 in the AAF/PHx protocol (B). Hepatic tissues were visualized by (a) volumetric rendering presenting the immunohistochemistry and (d,f,h) segmentation based reconstructions of lumina and protein expression. These techniques are presented combined in subpanels b, c, e, g, i, and j. In control rat liver (A, a-j) and day 9 in the AAF/PHx protocol (B, a-j) two portal areas merged in one end of the image stack (d) and continued as separate entities. Presented in green, lumina of slender portal bile ducts (b) along the portal vein connecting the portal areas could be traced in both livers. Whereas Dlk1 localized peripherally to the portal area in the AAF/PHx protocol (B;c,d) and was undetectable throughout the image stack from control liver (A;c,d), HAI-1 marked the epithelial cells in the entire biliary tree (A, e and f) and the HPC response (B;e,f). In control liver (A;g,h) Nidogen1 was only expressed in the portal area and circumscribed the biliary tree, and additionally embedded the HPC response in the AAF/PHx protocol (B;g,h). Combined staining of HAI-1 and Nidogen1 emphasized nidogen1 deposition around the HAI-1, expressing cells in the bile epithelium (A,B;i), and clarified Dlk1 as a marker of a subpopulation of HAI-1 expressing cells within the HPC response (B;j).
Applied primers and probes for real-time RT-PCR
| | 0.052 | |
| 1Primer forward | 5′-GGC GCC ACC ATT GAG AACT-3′ | 100 nM |
| 1Primer reverse | 5′-GCC AGG CGG GCA TTG-3′ | 100 nM |
| 1Probe | 5′-FAM-CAA GAT AGT CCT ACA GAT CG-BHQ-1-3′ | 200 nM |
| | 0.1 | |
| 1Primer forward | 5′-GCA TCT ACT GCA AGG TGA CCA A-3′ | 300 nM |
| 1Primer reverse | 5′-CCA CAG CTC AAC TTC TTC TGG AT-3′ | 300 nM |
| 2Probe | 5′-FAM-TGT CAG TGT TAA GAG AAA C-MGBNFQ-3′ | 280 nM |
| | 0.1 | |
| 1Primer forward | 5′-TGC TCT GGG AAG CAG ATG TAT C-3′ | 600 nM |
| 1Primer reverse | 5′-TGC GAA CCA TTC GGA TCA G-3′ | 600 nM |
| 2Probe | 5′-FAM-ACA AAA GCG GTG ATC C-MGBNFQ-3′ | 100 nM |
| | 0.1 | |
| 1Primer forward | 5′-TGG CTG TGG AGC GAG TTG T-3′ | 700 nM |
| 1Primer reverse | 5′-TGC CAC GGG CAT GGA-3′ | 700 nM |
| 1Probe | 5′-FAM-CCT TCC CCA TTG ACC CCA GAA TGC-BHQ-1-3′ | 240 nM |
| | 0.1 | |
| 1Primer forward | 5′-CAG TCA AGA ATC GGA GCT GAT G-3′ | 300 nM |
| 1Primer reverse | 5′-CAC TGC CAC CAC CTG TGA TG-3′ | 300 nM |
| 1Probe | 5′-FAM-CTG AAG CTT CCT GTG GTG CAG TCA TCC-BHQ-1-3′ | 140 nM |
Primer Express® Software Version 3 (Applied Biosystems) was employed to design primers within different exons and probes covering exon-exon borders to prevent amplification of genomic DNA. 1TAG Copenhagen, Copenhagen, Denmark; 2Applied Biosystems, Foster City, CA USA.
Applied antibodies for immunohistochemistry and immunofluorescence
| 1,*Matriptase | 1:500 | AF3946 | 7Vectastain Elite ABC | Not applicable | PK-6106 |
| 1,*HAI-1 | 1:500 | AF1141 | 7Vectastain Elite ABC | Not applicable | PK-6105 |
| 2,+Nidogen-1 | 1:1000 | ab14511 | 4Dako EnVision + System-HRP | Not applicable | K4008 |
| 3DLK1 | 1:50 | N/A | 4Dako EnVision + System-HRP | Not applicable | K4008 |
| 1Integrin-β6 | 1:50 | AF2389 | 8Alexa Fluor 488/594 | 1:400 | A-11055/A-11058 |
| 1Agrin | 1:100 | AF550 | 8Alexa Fluor 488/594 | 1:400 | A-11055/A-11058 |
| 1h/rOV-6 | 1:50 | MAB2020 (Clone OV-6) | 9Fluorescein | 1:200 | 715-095-151 |
| 1HAI-1 | 1:50 | AF1141 | 8Alexa Fluor 488/594 | 1:400 | A-11055/A-11058 |
| 1DLK1 | 1:100 | MAB114 (211309) | 8Alexa Fluor 488 | 1:400 | A-21141 |
| 3DLK1 | 1:250 | N/A | 8Alexa Fluor 594 | 1:400 | A-21207 |
| 4Desmin | 1:500 | M0760 (D33) | 9Fluorescein | 1:200 | 715-096-151 |
| 4Laminin | 1:2000 | Z0097 | 8Alexa Fluor 594 | 1:400 | A-11037/A-21207 |
| 5COL1A1 | 1:100 | AB755p | 8Alexa Fluor 594 | 1:400 | A-11037/A-21207 |
| 2Nidogen-1 | 1:1500 | ab14511 | 8Alexa Fluor 594 | 1:400 | A-11037/A-21207 |
| 6Ki67 | 1:2000 | NCL-Ki67p | 8Alexa Fluor 594 | 1:400 | A-11037/A-21207 |
1R&D Systems, Inc. Minneapolis, MN USA; 2AbCAM, Cambridge, UK; 3Polyclonal rabbit antibody; 4Dako A/S, Glostrup, Denmark; 5Milipore, Billerica, MA USA; 6Leica Microsystems Inc., Buffalo Grove, IL USA; 7Vector laboratories, Burlingame, CA USA; 8Life Technologies Europe BV, Nærum, Denmark; 9Jackson ImmunoResearch Europe Ltd., Suffolk, UK; *Sections were boiled in retrieval solution (St14) or retrieval solution, pH9 (Spint1) (Dako, catalog number S2367/S1699) for 20 min in a microwave oven and let to cool to room temperature for 20 min. +Sections were digested in proteinase K for 2.5 minutes at room temperature (Dako, catalog number S3020).